Table 3.

Treatment exposure in patients ≥70 years with squamous NSCLC

Parameter	nab-P/C (n=34)	P/C (n=30)
Median number of cycles administered	5	6
Median dose intensity
Taxane, mg/m2/week	76.69	63.16
Carboplatin, AUC/week	1.45	1.89
Median cumulative dose
Taxane, mg/m2	1,175.0	1,200.0
Carboplatin, AUC	26.3	36.0

Abbreviations: AUC, area under the curve; nab-P/C, nab-paclitaxel/carboplatin; NSCLC, non-small cell lung cancer; P/C, paclitaxel/carboplatin.